Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

ll only be valid to the extent that it has the requisite shareholder authority to issue the maximum number of Ordinary Shares that Darwin may be required to subscribe under the relevant subscription notice.

The Equity Finance Facility is conditional on the Company granting to Darwin a warrant to subscribe for up to 3,330,000 New Ordinary Shares at 1.5 pence per share at anytime within 36 months.of grant.

Irrevocable commitments from certain Directors and major Shareholders

The Directors who in aggregate hold 3,911,256 Existing Ordinary Shares, representing approximately 0.68 per cent. of the existing issued ordinary share capital of the Company, have irrevocably undertaken to vote in favour of the Resolutions at the General Meeting.

Certain major Shareholders, namely Robert Keith, and ACP IV LP who in aggregate hold 92,682,266 Existing Ordinary Shares representing approximately 16.06 per cent. of the existing issued ordinary share capital of the Company, have irrevocably undertaken not to take up their entitlements under the Open Offer and to vote in favour of the Resolutions at the General Meeting.

Current Trading and Prospects

Silence is a global leader in RNAi Therapeutics. The Company is nearing the completion of an open-label, dose escalation Phase I trial of its lead drug candidate Atu027 in patients with solid tumours. As at 30 June 2012, 34 patients have been treated with drug, which has been found to be safe and well tolerated. The trial is now expected to be completed in July 2012 with results available shortly thereafter.

In addition to Silence' own programmes, the Company has licensed its RNAi technology to several pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer and Quark. Silence has licensed its AtuRNAi technology to both Quark and Pfizer, which are collaborating on the development of PF-04523655 (PF-'655). In February 2012, Quark initiated a 264 patient Phase IIb trial of PF-'
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Capital, a firm specializing in acquiring and managing food ... the Slim-Fast brand from Unilever. Unilever will retain a ... were not disclosed. Slim-Fast is a branded ... shakes, powders, bars and snacks to retail customers throughout ... United Kingdom and Ireland.  The ...
(Date:7/10/2014)... 15, 2014 -- According to the International Atomic ... security comes from terrorists acquiring sufficient quantities of ... a crude nuclear explosive device. The IAEA also ... have involved gram-level quantities, which can be challenging ... to a new study appearing this week in ...
(Date:7/10/2014)... Understanding the basis of psychiatric disorders has been extremely ... increase risk but are insufficient to cause disease. Now ... Cell Press journal Cell Stem Cell describe ... genetic risks interact with other risk factors or environmental ... Their research pinpoints a genetic variant that may predispose ...
(Date:7/10/2014)... shelled out for crude 3-D glasses, polarized glasses, ... These basic devices, used to trick the brain ... be rendered obsolete with the introduction of new ... , TAU doctoral students Yuval Yifat, Michal Eitan, ... based on nanoantennas that could be used for ...
Breaking Biology Technology:Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... Neurognostics, Inc ., a Wisconsin company specializing in functional ... that the Food and Drug Administration (FDA) issued a ... MindState fDAD. MindState fDAD had previously received clearance ... The Special 510(k) allows Neurognostics to enhance fDAD by ...
... eMed , a Merge Healthcare company and a ... the release of Cedara I-ReadMammo digital mammography workstation ... product is designed to help organizations streamline breast ... mammography. , ,I-ReadMammo was designed to help ...
... a country that invented take out food, that is in love ... in motion, it was inevitable that work and indeed the workplace ... the place where knowledge work happens has shifted from primarily office ... a subway car, walking down the street or of course, hanging ...
Cached Biology Technology:Who moved the workplace? 2Who moved the workplace? 3Who moved the workplace? 4
(Date:7/11/2014)... of Entiat on Tuesday, July 8, 2014. Despite the ... over 1,000 acres by evening. Three outbuildings were damaged. ... the Washington Department of Natural Resources. The fire ... fire control strategies and tactics. Other cooperators include the ... Resources, (WA DNR), Bureau of Land Management, Chelan County ...
(Date:7/11/2014)... in German . ... uses the refraction of X-rays through a specimen instead ... this method are often of much higher quality than ... of Prof. Franz Pfeiffer are particularly interested in developing ... including X-ray phase-contrast imaging. One main goal is to ...
(Date:7/11/2014)... July 10, 2014---A team of researchers from The Chinese ... identified a gene of wild soybean linked to salt ... grow in saline soil. This study published online in ... unveil novel genomic information for crop improvement. , Soybean ... domestication and human selection, cultivated soybeans have less genetic ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... COLD SPRING HARBOR, N.Y. (Thurs., Oct. 1, 2009) ... choice for understanding where and when genes are expressed in ... physiological or environmental conditions. Recent discoveries have revolutionized our ... active in a much wider set of biological processes than ...
... Spatial Integrated Systems, Inc. ("SIS"), a leader in ... digital 3D data capture and processing technologies, announced ... been published for "system and method for generating ... No. US2009/0169095A1. , "We are pleased that our ...
... BATON ROUGE For Sophie Warny, LSU assistant professor of ... Natural Science, years of patience in analyzing Antarctic samples with ... and colleagues from around the world now have proof of ... 15.7 million years ago and lasted for a few thousand ...
Cached Biology News:Cold Spring Harbor Protocols features RNA analysis methods 2Spatial Integrated Systems, Inc. Files Patent Application 2Algae and pollen grains provide evidence of remarkably warm period in Antarctica's history 2Algae and pollen grains provide evidence of remarkably warm period in Antarctica's history 3Algae and pollen grains provide evidence of remarkably warm period in Antarctica's history 4
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
... Dermal Fibroblasts (Mouse/BalbC) and media. This cell ... and is guaranteed to provide an additional ... date supplied, when used with the recommended ... 18.5 ,Applications: ,Cultivation: Plate at ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
... statistical software package for scientists and engineers ... without being a statistical expert.Just answer a ... and SigmaStat suggests the appropriate test. It ... assumptions and suggests another test if your ...
Biology Products: